UnknownPhase 2/3

Effect of Gui-Lu-Er-Xian-Jiao-Wan on Intradialytic Hypotension

Taiwan50 participantsStarted 2022-09-01

Plain-language summary

Intradialytic hypotension (IDH), a common complication during hemodialysis (HD) could increase patients' morbidity and mortality. Previous studies considered that some Chinese herbal medicine (CHM) plays a complementary role in reducing the frequency of IDH. This trial is aimed to investigate the effect of Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) in patients with intradialytic hypotension.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * End stage renal disease treated with hemodialysis for ≥3 months * Receive a standard thrice-weekly hemodialysis schedule * More than 25% of hemodialysis sessions complicated by intradialytic hypotension Exclusion Criteria: * Active malignancy * Life-threatening conditions * Pregnancy * Recent participation in another clinical trial for intradialytic hypotension * History of hypersensitivity or contraindication to herbal medicine

What they're measuring

Intradialytic hypotension episode

Timeframe: Each time of dialysis during 12-weeks study period.

Trial details

NCT IDNCT05517993

SponsorChang Gung Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-31

Contact for this trial

Chun-Ting Liu

+88677317123 juntin0214@gmail.com

View on ClinicalTrials.gov More Intradialytic Hypotension trials